Comparative Evaluation of Focused Ultrasound Ablation Combined with Curettage and Transvaginal Repair in the Management of Cesarean Scar Pregnancy: A Retrospective Comparative Study

聚焦超声消融联合刮宫术和经阴道修补术治疗剖宫产瘢痕妊娠的比较评价:一项回顾性比较研究

阅读:1

Abstract

BACKGROUND: Cesarean scar pregnancy (CSP) is an uncommon and potentially life-threatening form of ectopic pregnancy characterized by embryo implantation within the scar tissue of a prior cesarean delivery. OBJECTIVE: The aim of this study is to compare clinical outcomes between focused ultrasound ablation surgery (FUAS) combined with suction curettage under hysteroscopic guidance and transvaginal debridement and repair surgery (TDRS) in the treatment of CSP. METHODS: A retrospective analysis was conducted on 78 patients with CSP and treated between 2017 and 2023. Among them, 25 received FUAS followed by hysteroscopic suction curettage, and 53 underwent TDRS. Key clinical indicators included intraoperative parameters, postoperative recovery, treatment costs, complications, and subsequent pregnancy outcomes. RESULTS: No significant differences were observed between the two groups in terms of intraoperative blood loss, decline rates of β-human chorionic gonadotropin and hemoglobin, or menstrual recovery. FUAS was associated with a significantly shorter operative time (34.96  ±  28.90 vs 60.13  ±  22.87 minutes, p <0.001), but also with a longer hospital stay (7.92  ±  2.98 vs 5.38  ±  1.61 days, p < 0.001) and higher treatment costs (Ren Min Bi (RMB) 15,278  ±  3980 vs RMB 9443  ±  1570, p <0.001). The treatment success rate was 76.00% for FUAS and 96.23% for TDRS (p=0.078). Among patients seeking fertility, post-treatment pregnancy rates were 71.43% in the FUAS group and 76.47% in the TDRS group (p > 0.05). No procedure-related complications were reported in either group. CONCLUSION: Both FUAS combined with curettage and TDRS demonstrated safety and effectiveness in the treatment of CSP, with favorable post-treatment fertility outcomes. TDRS was associated with shorter hospitalization and lower medical costs and may be preferable for certain CSP subtypes, such as type III. Treatment selection should be individualized based on clinical characteristics.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。